Benitec Biopharma (BNTC) Total Current Liabilities (2019 - 2025)

Benitec Biopharma has disclosed Total Current Liabilities across 7 years of filings, most recently posting $2.8 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $2.8 million, down 9.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.8 million (down 9.32% YoY), and the FY2025 annual result was $1.8 million, down 63.4% from the prior year.
• Total Current Liabilities came in at $2.8 million for Q4 2025 at Benitec Biopharma, up from $2.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $7.0 million in Q1 2025 to a low of $1.4 million in Q2 2021.
• The 5-year median for Total Current Liabilities is $2.9 million (2022), against an average of $3.2 million.
• Across the five-year window, Total Current Liabilities soared 218.36% in 2021 and slumped 63.4% in 2025, its largest moves.
• Benitec Biopharma's Total Current Liabilities stood at $2.5 million in 2021, then advanced by 0.36% to $2.5 million in 2022, then surged by 130.86% to $5.7 million in 2023, then sank by 46.24% to $3.1 million in 2024, then decreased by 9.32% to $2.8 million in 2025.
• The last three Total Current Liabilities figures came in at $2.8 million (Q4 2025), $2.0 million (Q3 2025), and $1.8 million (Q2 2025), per Business Quant data.